Free Trial

Wedbush Analysts Raise Earnings Estimates for ARTV

Artiva Biotherapeutics logo with Medical background

Key Points

  • Wedbush has raised its Q3 2025 earnings per share (EPS) estimate for Artiva Biotherapeutics to ($0.90), an improvement from the previous estimate of ($0.92).
  • The stock is currently rated as a "Buy" by six research analysts, with a consensus price target of $17.80.
  • Artiva Biotherapeutics recently reported a quarterly EPS of ($0.87), which missed analysts' expectations by ($0.03).
  • Looking to Export and Analyze Artiva Biotherapeutics Data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Wedbush lifted their Q3 2025 EPS estimates for Artiva Biotherapeutics in a note issued to investors on Thursday, August 7th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.90) for the quarter, up from their prior forecast of ($0.92). The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share. Wedbush also issued estimates for Artiva Biotherapeutics' Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.55) EPS, Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($3.02) EPS, FY2027 earnings at ($2.86) EPS, FY2028 earnings at ($3.05) EPS and FY2029 earnings at ($2.93) EPS.

A number of other research firms also recently commented on ARTV. Needham & Company LLC decreased their price objective on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, May 15th. HC Wainwright raised shares of Artiva Biotherapeutics to a "buy" rating and set a $12.00 price objective for the company in a report on Wednesday, June 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $17.80.

Check Out Our Latest Stock Analysis on Artiva Biotherapeutics

Artiva Biotherapeutics Stock Up 4.5%

Artiva Biotherapeutics stock opened at $2.76 on Monday. The company has a fifty day moving average price of $2.19 and a two-hundred day moving average price of $2.96. Artiva Biotherapeutics has a 12 month low of $1.47 and a 12 month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.03).

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its holdings in shares of Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock valued at $87,000 after acquiring an additional 3,361 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Artiva Biotherapeutics by 262.1% during the fourth quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company's stock valued at $100,000 after acquiring an additional 7,151 shares during the period. Deutsche Bank AG acquired a new position in shares of Artiva Biotherapeutics during the fourth quarter valued at $216,000. Barclays PLC boosted its holdings in shares of Artiva Biotherapeutics by 23.2% during the fourth quarter. Barclays PLC now owns 24,161 shares of the company's stock valued at $244,000 after acquiring an additional 4,545 shares during the period. Finally, Ground Swell Capital LLC acquired a new position in shares of Artiva Biotherapeutics during the second quarter valued at $38,000.

Artiva Biotherapeutics Company Profile

(Get Free Report)

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

Further Reading

Earnings History and Estimates for Artiva Biotherapeutics (NASDAQ:ARTV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Artiva Biotherapeutics Right Now?

Before you consider Artiva Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artiva Biotherapeutics wasn't on the list.

While Artiva Biotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines